BiotechTube
Ordaos Bio

Ordaos Bio

New York, United States· Est.
ordaos.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Ordaos Bio is an AI-driven drug design company pioneering a new class of therapeutics called miniPRO™ proteins. Its core technology is a multitask meta-learning Design Engine that generates and optimizes novel protein sequences from scratch, aiming to deliver drug candidates with superior properties in a fraction of the time of traditional methods. The company operates through internal programs and strategic partnerships, positioning itself as an enabler for faster, more efficient development of biologics. While still in the pre-clinical stage, its platform has demonstrated proof-of-concept in generating binders for targets like HER2 and SARS-CoV-2.

OncologyInfectious Disease

Technology Platform

The Ordaōs Design Engine: a multitask meta-learning AI platform that uses generative AI and reinforcement learning to design de novo mini-proteins (miniPRO™) from scratch, optimizing for structure, binding, stability, solubility, and developability.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The growing demand for novel biologic modalities that overcome the limitations of traditional antibodies creates a significant market for mini-proteins.
Ordaos's AI-driven platform offers the potential to drastically reduce discovery timelines and costs for partners, positioning it to capture value through high-margin partnership deals.
Success in early partnerships could lead to broader adoption across the pharmaceutical industry.

Risk Factors

The platform's core promise remains unproven in clinical development, representing a major technical and validation risk.
The company operates in a highly competitive landscape of AI-driven drug discovery platforms and must continuously demonstrate superior results to secure partnerships.
As a pre-revenue company with limited disclosed funding, it faces financial risk and will likely need to raise additional capital.

Competitive Landscape

Ordaos competes in the crowded AI-for-drug-discovery space against companies like Absci, Generate Biomedicines, and Recursion, though its specific focus on de novo mini-protein design is a differentiating niche. It also competes with traditional protein engineering firms and large biopharma internal teams. Its key competitive advantages are the claimed speed of its design cycle and the unique properties of its miniPRO™ modality.

More companies in Biologics / Biosimilars →More companies in United States →